QQQ0.13%

Trending

NOK7.78%

Info

home Symbol KYMRnews

Exchange: NASDAQ·Updated 07:34 PM EDT

KYMRKymera Therapeutics Inc

$110.34

$3.03

(2.67%)

Today

Closed $110.34

$0.00

(0.00%)

After Hours

EarningsAug 10

Mkt Cap$9.33B

Vol538,338.00

News

all

press releases

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PR Newswire NEW YORK, July 16, 2026 NEW YORK, July...

PR Newswire

More News

KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug

KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.

Zacks

Why Kymera Therapeutics Stock Popped This Week

Key PointsIt completed the enrollment phase of a Phase 2b study of its leading drug candidate...

Nasdaq News: Markets

Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study

KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.

Zacks

Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?

Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks

KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline

Kymera said that it finished enrolling patients nearly six months ahead of schedule in a mid-stage trial for KT-621.

Stocktwits

Stocks making the biggest moves midday: BlackBerry, Kymera Therapeutics, Apple, Wendy's & more

These are the stocks posting the largest moves midday...

CNBC: Top News

Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?

Kymera Therapeutics (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks

KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study

Kymera shares climb after patient dosing begins in a phase I KT-485 study, triggering a $20 million milestone payment from Sanofi.

Zacks

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

PR Newswire

...

Advertisement|Remove ads.